After vancomycin, the prebiotic 2’-FL shows no detectable benefit for the microbiome

A prebiotic studied after a specific antibiotic

The analysis covers a subgroup of 18 participants from a randomized, double-blind, placebo-controlled trial. The researchers studied eight weeks of 2’-FL supplementation after seven days of vancomycin. The abstract provided does not specify the prebiotic dose.

They used metagenomic sequencing to characterize the gut microbiome and the resistome—the full set of antibiotic resistance genes detected. Samples were analyzed before vancomycin, after its use, and after the supplementation period.

Microbiome disruption, with no improvement in recovery from 2’-FL

After seven days of vancomycin, microbial richness and diversity were disrupted, and microbiome composition had changed. These measurements describe the microbial community. On their own, they cannot quantify the consequences for participants’ health.

After eight weeks, the researchers detected no improvement in microbiome recovery with 2’-FL compared with placebo. The abstract provides no effect size to precisely quantify the difference between groups. With such a small sample, the absence of a detected difference does not demonstrate the absence of any effect.

Resistance genes do not exactly track microbial diversity

Vancomycin did not alter the overall richness or diversity of the resistome, but the presence of certain resistance genes changed. An overall measure can therefore remain stable while individual components change.

2’-FL showed no detectable differential effect on resistome richness, diversity, or composition compared with placebo. These observations do not support a conclusion that the risk of resistant infection changed—a clinical outcome not reported in the abstract.

A promise of recovery that remains unproven

The hypothesis that a prebiotic might limit antibiotic-related disruption is not enough to establish its effectiveness. Under the conditions studied, 2’-FL provided no detectable benefit on the measures reported.

This finding cannot be generalized to all prebiotics, all antibiotics, or other populations. The source dossier contains only the article’s PubMed abstract, identified by DOI 10.1080/19490976.2026.2746814. The full text, funding, and conflicts of interest have not been checked.

What we can take away

This small analysis does not support the promise of better microbiome recovery with 2’-FL after vancomycin. Nor does it demonstrate that all prebiotics are ineffective after every antibiotic.